Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 447-453

  Hassan, Raffit ^a   Remaley, Alan T ^a   Sampson, Maureen L ^a   Zhang, Jingli ^a   Cox, Derrick D ^a   Pingpank, James ^a   Alexander, Richard ^a   Willingham, Mark ^b   Pastan, Ira ^a   Onda, Masanori ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; MESOTHELIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; OVARY CANCER; PATIENT MONITORING; PRIORITY JOURNAL; SERUM; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 31544439933     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1477     Document Type: Article

References (30)

1. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40.
2. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28.
3. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8.
4. Chang K, Pastan I, Willingham M. Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. Int J Cancer 1992;51:548-54.
5. Hassan R, Bera T Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42.
6. Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 1994;269:805-8.
7. Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 1995;270:21984-90.
8. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000;20:2902-6.
9. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2003;279:9190-8.
10. Ho M, Hassan R, Zhang J, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005;11:3814-20.
11. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297-306.
12. Censullo P, Davitz MA. How GPI-anchored proteins turnover: or where do they go after arrival at the plasma membrane. Semin Immunol 1994;6:81-8.
13. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999;96:11531-6.
14. Robinson BWS, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
15. Onda M, Willingham M, Nagata S, et al. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, western blotting and ELISA. Clin Cancer Res 2005;11:5840-6.
16. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560-7.
17. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999;17:568-72.
18. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin Nat Med 1996;2:350-3.
19. Hochberg YA. Sharper Bonferroni procedure for multiple tests of significance. Biometrika 1998;75:800-2.
20. Bast RC, Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003;21:200-5s.
21. Doherty AP, Bower M, Christmas TJ. The role of tumor markers in the diagnosis and treatment of testicular germ cell cancers. Br J Urol 1997;79:247-52.
22. Gray MA. Clinical use of serum prostate-specific antigen: a review. Clin Lab 2005;51:127-33.
23. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373-81.
24. Kondoh G, Tojo H, Nakatani Y, et al. Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization. Nat Med 2005;11:160-6.
25. Sharom FJ, Lento MT. Glycosylphosphatidylinositol-anchored proteins: structure, function, and cleavage by phosphatidylinositol-specific phospholipase C. Biochem Cell Biol 2002;80:535-49.
26. Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 1987;165:848-64.
27. Luhrs CA, Slomiany BL. A human membrane-associated folate binding protein is anchored by a glycosylphosphatidylinositol tail. J Biol Chem 1989;264:21446-9.
28. Huang Y, Fayad R, Smock A, Ullrich AM, Qiao L. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine. Cancer Res 2005;65:6990-8.
29. Sacks TL, Gum JR, Low MG, Kim YS. Release of carcinoembryonic antigen from human colon cancer cells by phosphatidylinositol-specific phospholipase C. J Clin Invest 1988;82:586-93.
30. Yamamoto Y, Hirakawa E, Mori S, et al. Cleavage of carcinoembryonic antigen induces metastatic potential in colorectal carcinoma. Biochem Biophys Res Commun 2005;333:223-9.